-1366x0.jpg)
This year’s conference will take place on Friday, April 18, 2025, at the Pan Pacific Hotel Hanoi (1 Thanh Nien Road, Ba Dinh, Hanoi).
We are honored to accompany the conference as a sponsor. GENTIS’ booth will offer many exciting activities and attractive gifts for delegates. Additionally, the GENTIS booth will focus on presenting solutions for genetic screening and diagnosis in the field of reproductive support, particularly the three new PGT testing packages: PGT +100 rare diseases, PGT NEXT, and PGT UPGRADE.
One of the key advantages of PGT-M testing at GENTIS is the ability to analyze over 100 single-gene genetic diseases with high accuracy, allowing for the detection of even small DNA variants that may cause disease. By applying next-generation sequencing (NGS) technology combined with family-specific marker design, PGT-M ensures accuracy in identifying healthy embryos, thus increasing the chances of having a child free from genetic disorders. In addition to advanced technology, PGT-M for 100+ rare diseases also includes support from a dedicated genetic counseling team, accompanying patients before, during, and after testing.
PGT NEXT is a pre-embryo transfer genetic test capable of detecting aneuploidy on 24 chromosomes, additional abnormalities, and chromosomal deletions. It can also detect embryos with triploidy or monosomy. This helps avoid transferring embryos with these abnormalities, while also preventing wasting euploid embryos that have fertilization issues (0PN, 1PN, and 2.1/3PN). Additionally, PGT NEXT provides genetic information for embryo selection prior to transfer.
The combination of whole-genome sequencing (NGS) with SNP analysis enhances the resolution of genetic screening to detect aneuploidy. This method allows for the detection of monosomic and trisomic chromosomes, increasing the number of euploid embryos available for transfer by identifying truly diploid embryos among abnormal fertilized embryos (0PN, 1PN, 2.1PN, 3PN). Furthermore, SNP analysis ensures accurate identification of whether an embryo shares a genetic relationship with other embryos in the same group, reducing the risk of sample mix-ups due to procedural errors.
PGT UPGRADE is a pre-embryo transfer genetic test capable of detecting aneuploidy on 24 chromosomes, additional abnormalities, chromosomal deletions larger than 5 Mb, and particularly the ability to detect balanced translocations inherited from parents. Additionally, PGT UPGRADE provides genetic information for embryo selection before transfer.
At the conference, Dr. Pham Dinh Minh (Director of R&D at GENTIS) will present a report titled: "Factors Affecting the Outcome of Mosaic Embryos from a Genetic Lab Perspective."
We cordially invite doctors, embryologists, and experts to visit the GENTIS booth to update themselves on the most modern and advanced pre-implantation genetic screening solutions, serving the healthcare needs of the Vietnamese people.
